Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00399126 · ClinicalTrials.gov registry record · Phase 1
Phase I Trial of Paclitaxel With Perifosine
A Phase 1 study, sponsored by AEterna Zentaris.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT00399126 is a Phase 1 study that has completed, run by AEterna Zentaris. The registered enrollment target is 24 participants.
The verdict
NCT00399126, a Phase 1 study, has completed, sponsored by AEterna Zentaris.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This is a study of the drug perifosine given in combination with paclitaxel. Perifosine is an oral anti-cancer agent that has been used in more than 140 people. Paclitaxel is a standard chemotherapy agent used in many types of cancer. This study is designed to determine the highest dose of perifosine that can be administered to people every day while they are receiving paclitaxel in one of two regimens, without severe or prolonged nausea, vomiting and diarrhea. This study starts with patients taking 50 mg/day and goes up to 150 mg/day.
Interventions
- DRUG Paclitaxel
- DRUG Perifosine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2004-11 |
| Est. Completion | 2011-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00399126
The ClinicalTrials.gov registry entry for NCT00399126 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AEterna Zentaris, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Paclitaxel is the first listed.
NCT00399126 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00399126 about?
NCT00399126 is a clinical study titled "Phase I Trial of Paclitaxel With Perifosine". This is a study of the drug perifosine given in combination with paclitaxel. Perifosine is an oral anti-cancer agent that has been used in more than 140 people. Paclitaxel is a standard chemotherapy agent used in many types of cancer. This study is designed to determine the highest dose of perifosin...
What is the current status of trial NCT00399126?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2004-11. Estimated completion is 2011-10.
What interventions are being tested in trial NCT00399126?
The interventions under investigation include: Paclitaxel (DRUG), Perifosine (DRUG).
Who is sponsoring clinical trial NCT00399126?
This trial is sponsored by AEterna Zentaris, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.